

Contents

| | |
|--------------------------|-------------|
| About the Editors | <i>xv</i> |
| Preface | <i>xvii</i> |
| Acknowledgments | <i>xix</i> |

Section I Introduction 1

| | | |
|----------|--|-----------|
| 1 | Karen J. Brewer (1961–2014): A Bright Star that Burned Out Far Too Soon | 3 |
| | <i>Seth C. Rasmussen</i> | |
| 1.1 | Introduction | 3 |
| 1.2 | Early Years | 4 |
| 1.3 | Graduate Studies and Clemson University | 6 |
| 1.4 | Postdoctoral Research and the University of California, Berkeley | 11 |
| 1.5 | Washington State University: Beginning an Independent Career | 13 |
| 1.6 | Move to Virginia Tech | 15 |
| 1.7 | Collaboration with Brenda Winkel and the Study of Metal-DNA Interactions | 16 |
| 1.8 | A Return to Where It All Started: Photochemical H ₂ Production | 18 |
| 1.9 | A Career Cut Tragically Short | 19 |
| 1.10 | Karen's Legacy | 20 |
| | Acknowledgments | 20 |
| | References | 20 |
| 2 | Basic Coordination Chemistry of Ruthenium | 25 |
| | <i>Mark A. W. Lawrence, Jimmie L. Bullock, and Alvin A. Holder</i> | |
| 2.1 | Coordination Chemistry of Ruthenium | 25 |
| 2.1.1 | The Element | 25 |
| 2.1.2 | Stereochemistry and Common Oxidation States | 26 |
| 2.1.2.1 | Ruthenium in Low Oxidation States | 27 |
| 2.1.2.2 | Chemistry of Ruthenium(II) and (III) | 31 |
| 2.1.2.3 | Higher Oxidation States of Ruthenium | 36 |
| 2.1.3 | Conclusion | 37 |
| | References | 37 |

Section II Artificial Photosynthesis 43**3 Water Oxidation Catalysis with Ruthenium 45***Andrea Sartorel*

- 3.1 Introduction 45
 - 3.1.1 Energy Issue and Energy from the Sun 45
 - 3.1.2 Photosynthesis and Solar Fuels 46
 - 3.1.3 Water Oxidation 48
 - 3.1.4 Artificial Water Oxidation 49
- 3.2 Ruthenium in Water Oxidation Catalyst 50
 - 3.2.1 Ruthenium Oxide 50
 - 3.2.2 Molecular Ruthenium WOC 52
 - 3.2.2.1 Meyer's Blue Dimer 53
 - 3.2.2.2 The Ru-Hbpp Catalyst 54
 - 3.2.2.3 Single-Site Ru-WOCs 55
 - 3.2.2.4 Heptacoordinated Ru Intermediates 56
 - 3.2.3 Polyoxometalates: The Bridge Between Metal Oxides and Coordination Complexes 57
- 3.3 Conclusions and Perspectives 60
- References 61

4 Ruthenium- and Cobalt-Containing Complexes and Hydrogenases for Hydrogen Production 67*Michael J. Celestine, Raj K. Gurung, and Alvin A. Holder*

- 4.1 Introduction 67
- 4.2 (A) Ruthenium- and Cobalt-Containing Complexes for Hydrogen Production 68
 - 4.2.1 Nonbridged Systems 68
 - 4.2.2 Bridged Systems 70
- 4.3 (B) Ruthenium(II)-Containing Complexes and Hydrogenases for Hydrogen Generation in Aqueous Solution 77
 - 4.3.1 Hydrogenases 77
 - 4.3.2 Hydrogenases with Ruthenium(II) Complexes 78
- 4.4 Conclusions 84
- References 85

Section III Applications in Medicine 89**5 Ligand Photosubstitution Reactions with Ruthenium Compounds: Applications in Chemical Biology and Medicinal Chemistry 91***Samantha L. Hopkins and Sylvestre Bonnet*

- 5.1 Introduction 91
- 5.2 Caging and Uncaging Biologically Active Ligands with a Nontoxic Ruthenium Complex 92
- 5.3 Caging Cytotoxic Ruthenium Complexes with Organic Ligands 96

| | | |
|----------|---|------------|
| 5.4 | Low-Energy Photosubstitution | 100 |
| 5.4.1 | Introduction | 100 |
| 5.4.2 | Modulating Ru Photophysics by Ligand Modulation | 100 |
| 5.4.3 | Upconversion (UC) | 105 |
| 5.4.3.1 | Triplet–Triplet Annihilation Upconversion | 105 |
| 5.4.3.2 | Upconverting Nanoparticles (UCNPs) | 106 |
| 5.4.3.3 | Two-Photon Absorption (TPA) Photosubstitution | 109 |
| 5.5 | Conclusions | 110 |
| | References | 111 |
| 6 | Use of Ruthenium Complexes as Photosensitizers in Photodynamic Therapy | 117 |
| | <i>Lothar Lilge</i> | |
| 6.1 | Introduction | 117 |
| 6.2 | The Basics of Photodynamic Therapy | 118 |
| 6.2.1 | Singlet Oxygen Production | 120 |
| 6.2.2 | Other Radical Production | 120 |
| 6.2.3 | PDT Dose Definition | 120 |
| 6.2.3.1 | PDT Dosimetry <i>In Vitro</i> | 122 |
| 6.2.3.2 | PDT Dosimetry <i>In Vivo</i> | 124 |
| 6.2.3.3 | Oxygen Consumption Model | 125 |
| 6.2.3.4 | <i>In Vivo</i> Tissue Response Models | 125 |
| 6.2.4 | PDT and Immunology | 126 |
| 6.3 | Status of Ru Photosensitizing Complexes | 126 |
| 6.3.1 | Photostability for Ru-PS Complexes | 128 |
| 6.3.2 | Long Wavelength Activation of Ru(II)-PS Complexes | 128 |
| 6.4 | Issues to Be Considered to Further Develop Ru-Based Photosensitizers | 129 |
| 6.4.1 | Subcellular Localization | 130 |
| 6.4.2 | Ruthenium Complex Photosensitizers and the Immune Response | 131 |
| 6.5 | Future Directions for Ru-PS Research | 131 |
| 6.6 | Conclusion | 132 |
| | References | 132 |
| 7 | Photodynamic Therapy in Medicine with Mixed-Metal/Supramolecular Complexes | 139 |
| | <i>Jimmie L. Bullock and Alvin A. Holder</i> | |
| 7.1 | Introduction | 139 |
| 7.2 | Platinum and Rhodium Centers as Bioactive Sites | 140 |
| 7.2.1 | Platinum(II)-Based Chemotherapeutics | 140 |
| 7.2.2 | Rhodium(III) as a Bioactive Site | 141 |
| 7.3 | Supramolecular Complexes as DNA Photomodification Agents | 142 |
| 7.4 | Mixed-Metal Complexes as Photodynamic Therapeutic Agents | 143 |
| 7.4.1 | Photosensitizers with a Ru(II) Metal Center Coupled to Pt(II) Bioactive Sites | 143 |

- 7.4.1.1 Binuclear Complexes with Ru(II) and Pt(II) Metal Centers with Bidentate Ligands 143
- 7.4.1.2 Binuclear and Trinuclear Complexes with Ru, Pt with Tridentate Ligands 146
- 7.4.2 Photosensitizers with a Ru(II) Metal Center Coupled to Rh(III) Bioactive Sites 147
 - 7.4.2.1 Trinuclear Complexes with Ru(II), Rh(III), and Ru(II) Metal Centers 147
 - 7.4.2.2 Binuclear Complexes with Ru(II) and Rh(III) Metal Centers 149
- 7.4.3 Photosensitizers with a Ru(II) Metal Center Coupled to Other Bioactive Sites 150
 - 7.4.3.1 Binuclear Complexes with Ru(II) and Cu 150
 - 7.4.3.2 Binuclear Complexes with Ru(II) and Co(III) Metal Centers 151
 - 7.4.3.3 Binuclear Complexes with Ru(II) and V(IV) Metal Centers 151
 - 7.4.3.4 Applications of Ru(II) Metal Centers in Nanomedicine 152
- 7.5 Summary and Conclusions 155
 - Abbreviations 156
 - References 157

- 8 Ruthenium Anticancer Agents En Route to the Tumor: From Plasma Protein Binding Agents to Targeted Delivery 161**
Muhammad Hanif and Christian G. Hartinger
 - 8.1 Introduction 161
 - 8.2 Protein Binding Ru^{III} Anticancer Drug Candidates 163
 - 8.2.1 Ru^{III} Anticancer Drug Candidates Targeting Primary Tumors 163
 - 8.2.2 Antimetastatic Ru^{III} Compounds 165
 - 8.3 Functionalization of Macromolecular Carrier Systems with Ru Anticancer Agents 166
 - 8.3.1 Proteins as Delivery Vectors for Organometallic Compounds 166
 - 8.3.2 Polymers and Liposomes as Delivery Systems for Bioactive Ruthenium Complexes 168
 - 8.3.3 Dendrimers 169
 - 8.4 Hormones, Vitamins, and Sugars: Ruthenium Complexes Targeting Small Molecule Receptors 169
 - 8.5 Peptides as Transporters for Ruthenium Complexes into Tumor Cells and Cell Compartments 173
 - 8.6 Polynuclear Ruthenium Complexes for the Delivery of a Cytotoxic Payload 174
 - 8.7 Summary and Conclusions 175
 - Acknowledgments 175
 - References 176

- 9 Design Aspects of Ruthenium Complexes as DNA Probes and Therapeutic Agents 181**
Madeleine De Beer and Shawn Swavey
 - 9.1 Introduction 181
 - 9.2 Physical Interaction to Disrupt DNA Structure 181

- 9.2.1 Irreversible Covalent Binding 182
- 9.2.2 Intercalation 184
- 9.2.3 Additional Noncovalent Binding Interactions 185
- 9.3 Biological Consequences of Ru-Complex/DNA Interactions 186
- 9.4 Effects of Ru Complexes on Topoisomerases and Telomerase 191
- 9.5 Summary and Conclusions 196
- References 197

10 Ruthenium-Based Anticancer Compounds: Insights into Their Cellular Targeting and Mechanism of Action 201

António Matos, Filipa Mendes, Andreia Valente, Tânia Morais, Ana Isabel Tomaz, Philippe Zinck, Maria Helena Garcia, Manuel Bicho, and Fernanda Marques

- 10.1 Introduction 201
- 10.2 Cellular Uptake 204
- 10.3 DNA and DNA-Related Cellular Targets 205
- 10.4 Targeting Signaling Pathways 207
- 10.5 Targeting Enzymes of Specific Cell Functions 207
- 10.6 Targeting Glycolytic Pathways 209
- 10.7 Macromolecular Ruthenium Conjugates: A New Approach to Targeting 211
- 10.8 Conclusions 214
- References 215

11 Targeting cellular DNA with Luminescent Ruthenium(II) Polypyridyl Complexes 221

Martin R. Gill and Jim A. Thomas

- 11.1 Introduction 221
- 11.1.1 DNA-Binding Modes of Small Molecules 222
- 11.1.2 Metal Complexes and DNA 223
- 11.2 $[\text{Ru}(\text{bpy})_2(\text{dppz})]^{2+}$ and the DNA “Light-Switch” Effect 224
- 11.3 Cellular Uptake of RPCs and Application as DNA-Imaging Agents 226
- 11.3.1 Mononuclear Complexes 226
- 11.3.2 Dinuclear Complexes 228
- 11.3.3 Cyclometalated Systems 228
- 11.4 Alternative Techniques to Assess Cellular Uptake and Localization 231
- 11.5 Toward Theranostics: luminescent RPCs as Anticancer Therapeutics 232
- 11.6 Summary and Conclusions 234
- References 235

12 Biological Activity of Ruthenium Complexes With Quinoline Antibacterial and Antimalarial Drugs 239

Jakob Kljun and Iztok Turel

- 12.1 Introduction 239

- 12.2 Antibacterial (Fluoro)quinolones 240
 - 12.2.1 Quinolones and Their Interactions with Metal Ions 241
 - 12.2.2 Ruthenium and Quinolones 241
 - 12.2.3 Ruthenium and HIV Integrase Inhibitor Elvitegravir 245
- 12.3 Antibacterial 8-Hydroxyquinolines 246
 - 12.3.1 Mode of Action of 8-Hydroxyquinoline Agents 246
 - 12.3.2 Ruthenium and 8-Hydroxyquinolines 247
- 12.4 Antimalarial 4-Aminoquinolines 248
 - 12.4.1 Mechanism of Action of Antimalarial Quinoline Agents 248
- 12.5 Metallocene Analogues of Chloroquine 249
- 12.6 Conclusions 252
- References 252

- 13 Ruthenium Complexes as NO Donors: Perspectives and Photobiological Applications 257**
Loyanne C.B. Ramos, Juliana C. Biazzotto, Juliana A. Uzuelli, Renata G. de Lima, and Roberto S. da Silva
 - 13.1 Introduction 257
 - 13.2 Photochemical Processes of Some Nitrogen Oxide Derivative–Ruthenium Complexes 258
 - 13.2.1 Metal-Ligand Charge-Transfer Photolysis of {Ru-NO}⁶ 258
 - 13.2.2 Nitrosyl Ruthenium Complexes: Visible-Light Stimulation 261
 - 13.3 Photobiological Applications of Nitrogen Oxide Compounds 265
 - 13.3.1 Photovasorelaxation 265
 - References 268

- 14 Trends and Perspectives of Ruthenium Anticancer Compounds (Non-PDT) 271**
Michael A. Jakupec, Wolfgang Kandioller, Beatrix Schoenhacker-Alte, Robert Trondl, Walter Berger, and Bernhard K. Keppler
 - 14.1 Introduction 271
 - 14.2 Ruthenium(III) Compounds 272
 - 14.2.1 NAMI-A 273
 - 14.2.1.1 Biotransformation 273
 - 14.2.1.2 Antimetastatic Activity 274
 - 14.2.1.3 Mode of Action 274
 - 14.2.1.4 Clinical Studies and Perspectives 275
 - 14.2.2 KP1019/NKP-1339 276
 - 14.2.2.1 Tumor Targeting Mediated by Plasma Proteins 276
 - 14.2.2.2 Activation by Reduction 277
 - 14.2.2.3 Mode of Action 278
 - 14.2.2.4 Clinical Studies and Perspectives 281
 - 14.3 Organoruthenium(II) Compounds 282
 - 14.3.1 Ruthenium(II)–Arene Compounds in Preclinical Development 282
 - 14.3.1.1 Organoruthenium Complexes Bearing Bioactive Ligand Scaffolds 284

| | | |
|-----------|--|------------|
| 14.3.1.2 | Cytotoxic Organoruthenium Complexes without Activation by Aqueation | 285 |
| | References | 286 |
| 15 | Ruthenium Complexes as Antifungal Agents | 293 |
| | <i>Claudio L. Donnici, Maria H. Araujo, and Maria A. R. Stoianoff</i> | |
| 15.1 | Introduction | 293 |
| 15.2 | Antifungal Activity Investigations of Ruthenium Complexes | 304 |
| 15.2.1 | Ruthenium Complexes with Activity against Several Pathogenic Fungi Species: Dinuclear, Trinuclear, and Tetranuclear ruthenium Polydentate Polypyridil ligands, Heterotrimetallic di-Ruthenium-Mono-Palladium Complexes, Dinuclear bis- β -Diketones and Pentadithiocarbamate Ligands | 304 |
| 15.2.2 | Aromatic and Heteroaromatic Ligands in Ru Monometallic Centers (Pyridine, Phenantroline, Terpyridine, Quinoline, and Phenazine) | 305 |
| 15.2.3 | Schiff bases, Thiosemicarbazones, and Chalcones | 307 |
| 15.2.3.1 | Schiff bases (Tetradentate Salen Like, Tridentate, and bidentate) | 307 |
| 15.2.3.2 | Thiosemicarbazones | 309 |
| 15.2.3.3 | Chalcone Derivatives | 310 |
| 15.2.4 | Other ligands (Dithio-Naphtyl-Benzamide, Arylazo, Catecholamine, Organophosphorated, Hydridotris(pyrazolyl)borate and Bioactive Azole Ligands) | 310 |
| 15.3 | Conclusion | 312 |
| | References | 313 |
| | Index | 319 |

